TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07229625: A Phase III, Randomized, Controlled, Open-Label, Multicenter Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy a

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 604 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07229625 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07229625 Rescue Dossier →